MX2013012785A - Tratamiento del mieloma multiple. - Google Patents

Tratamiento del mieloma multiple.

Info

Publication number
MX2013012785A
MX2013012785A MX2013012785A MX2013012785A MX2013012785A MX 2013012785 A MX2013012785 A MX 2013012785A MX 2013012785 A MX2013012785 A MX 2013012785A MX 2013012785 A MX2013012785 A MX 2013012785A MX 2013012785 A MX2013012785 A MX 2013012785A
Authority
MX
Mexico
Prior art keywords
multiple myeloma
myeloma treatment
subject
treatment
prevalence
Prior art date
Application number
MX2013012785A
Other languages
English (en)
Inventor
Christopher John Burns
Andrew Spencer
Katherine Anne Monaghan
Original Assignee
Ym Biosciences Australia Pty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47107683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013012785(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ym Biosciences Australia Pty filed Critical Ym Biosciences Australia Pty
Publication of MX2013012785A publication Critical patent/MX2013012785A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

para tratar un sujeto que presenta mieloma múltiple en un estadio caracterizado por un aumento en la prevalencia de células de mieloma múltiple que (1) son no respondedoras a IL-6 y/o (2) tienen un fenotipo CD45-, que comprende administrar al sujeto una cantidad de un compuesto de fórmula Ib: (ver Fórmula).
MX2013012785A 2011-05-02 2012-05-01 Tratamiento del mieloma multiple. MX2013012785A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161481425P 2011-05-02 2011-05-02
PCT/AU2012/000462 WO2012149602A1 (en) 2011-05-02 2012-05-01 Multiple myeloma treatment

Publications (1)

Publication Number Publication Date
MX2013012785A true MX2013012785A (es) 2014-05-28

Family

ID=47107683

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012785A MX2013012785A (es) 2011-05-02 2012-05-01 Tratamiento del mieloma multiple.

Country Status (20)

Country Link
US (1) US20140171433A1 (es)
EP (1) EP2704722A4 (es)
JP (1) JP2014514337A (es)
KR (1) KR20140081757A (es)
CN (1) CN103533939A (es)
AP (1) AP2013007281A0 (es)
AU (1) AU2012250491A1 (es)
BR (1) BR112013028420A2 (es)
CA (1) CA2834414A1 (es)
CL (1) CL2013003143A1 (es)
CO (1) CO6900134A2 (es)
EA (1) EA201391591A1 (es)
IL (1) IL228981A0 (es)
MA (1) MA35129B1 (es)
MD (1) MD20130089A2 (es)
MX (1) MX2013012785A (es)
PE (1) PE20140750A1 (es)
SG (1) SG194212A1 (es)
WO (1) WO2012149602A1 (es)
ZA (1) ZA201308918B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101566840B1 (ko) 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
ES2946179T3 (es) * 2014-05-28 2023-07-13 Onco Tracker Inc Efectos antineoplásicos de inhibidores de JAK2 en combinación con derivados de talidomida y glucocorticoides
TWI681954B (zh) * 2014-06-12 2020-01-11 美商西爾拉癌症醫學公司 Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺
US10428146B2 (en) 2014-07-22 2019-10-01 Cb Therapeutics, Inc. Anti PD-1 antibodies
JP6909153B2 (ja) 2014-08-05 2021-07-28 アポロミクス インコーポレイテッド 抗ｐｄ−ｌ１抗体
CN106316963B (zh) * 2015-06-26 2021-06-08 苏州泽璟生物制药股份有限公司 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物
CN105837515B (zh) * 2016-04-06 2018-08-03 中国药科大学 一种JAK抑制剂Momelotinib的制备方法
CN106075046A (zh) * 2016-07-31 2016-11-09 孙书芳 一种治疗肝肾阴虚型多发性骨髓瘤的中药
US10487321B2 (en) * 2016-09-29 2019-11-26 PZM Diagnostics, LLC Method of extraction of genomic DNA for molecular diagnostics and application
WO2019055930A1 (en) * 2017-09-15 2019-03-21 University Of Iowa Research Foundation METHODS OF IDENTIFYING MYELOMA TUMOR INITIATOR CELLS AND TARGETED THERAPY
CN109045040A (zh) * 2018-03-12 2018-12-21 首都医科大学附属北京天坛医院 Cyt387用于制备治疗神经胶质瘤的药物的应用
CN111100076A (zh) * 2019-12-30 2020-05-05 武汉九州钰民医药科技有限公司 Jak抑制剂莫美洛替尼的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06012698A (es) * 2004-05-05 2007-02-14 Celgene Corp Metodos y composiciones que utilizan farmacos inhibidores de citocina selectiva para el tratamiento y manejo de canceres y otras enfermedades.
MX2009005649A (es) * 2006-11-27 2009-06-08 Ares Trading Sa Tratamiento para mieloma multiple.
KR101566840B1 (ko) * 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도

Also Published As

Publication number Publication date
AU2012250491A1 (en) 2013-05-02
CO6900134A2 (es) 2014-03-20
MD20130089A2 (ro) 2014-05-31
KR20140081757A (ko) 2014-07-01
PE20140750A1 (es) 2014-07-06
WO2012149602A1 (en) 2012-11-08
JP2014514337A (ja) 2014-06-19
EA201391591A1 (ru) 2014-12-30
IL228981A0 (en) 2013-12-31
MA35129B1 (fr) 2014-05-02
EP2704722A1 (en) 2014-03-12
CA2834414A1 (en) 2012-11-08
CN103533939A (zh) 2014-01-22
CL2013003143A1 (es) 2014-07-04
SG194212A1 (en) 2013-11-29
BR112013028420A2 (pt) 2017-01-24
AP2013007281A0 (en) 2013-11-30
US20140171433A1 (en) 2014-06-19
EP2704722A4 (en) 2014-11-05
ZA201308918B (en) 2014-08-27

Similar Documents

Publication Publication Date Title
MX2013012785A (es) Tratamiento del mieloma multiple.
PH12018501410A1 (en) Therapeutically active compounds and their method of use
MY183661A (en) Treatment of cancer with tor kinase inhibitors
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
MX342951B (es) Composiciones terapeuticamente activas y su metodo de uso.
NZ723971A (en) Methods and compositions for treating ewings sarcoma family of tumors
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2014000515A (es) Metodo de tratamiento de inflamacion e himpertencion secuestrante de gama -cetoaldehido.
EA201490800A1 (ru) Способ ингибирования деубиквитинирующей активности
IN2014CN04634A (es)
PH12014500990A1 (en) Methods for treating gout flares
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
MX343968B (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
MX2015013240A (es) Método para proporcionar neuroprotección ocular.
MX2014003223A (es) Composiciones y metodos para tratar el cancer usando el inhibidor de pi3kbeta y el inhibidor de la via de mapk, incluidos los inhibidores de mek y raf.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
MX348147B (es) Biarilsulfonamidas utiles en el tratamiento de la inflamacion y cancer.
MX2014005399A (es) Metodos para tratar gota en sub-poblaciones de pacientes.
MX2016002307A (es) Tratamiento para el cancer.
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy